Search the Community
Showing results for tags 'corticosteroids'.
Found 1 result
Corticosteroid-sparing (CS) benefit of intravenous immunoglobulin (IVIg) in systemic sclerosis-associated myopathy (SScAM): A comparative study in 52 patients. This study suggests the benefit of IVIg as adjunctive therapy, with an acceptable tolerance profile, and supports its use as a CS-sparing agent, in SScAM. PubMed, Autoimmun Rev, 2020 Jan;19(1):102431. (Also see Treatments for Dermatomyositis and Polymyositis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.